Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics
NCT ID: NCT00689325
Last Updated: 2010-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
158 participants
OBSERVATIONAL
2008-04-30
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with one atypical antipsychotic\* (for a first/new episode or a switch of therapy) for at least 2 weeks and maximum 8 weeks prior to the first study visit.
* Patient takes an AAP according to local SPC and current medical practice
* The patient must be able to understand and comply with the study requirements as judged by the investigator, e.g. patient must be able to read and write
Exclusion Criteria
* Since the use of clozapine is limited, due to, among other things, the risk for agranulocytosis, patients on treatment with this '2nd line'AAP are excluded.
* Previous enrolment or treatment in the present NIS
* Known allergy to the prescribed AAP or any of its substances
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca, Medical Science, Wilmington USA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Alphen, , Netherlands
Research Site
Amersfoort, , Netherlands
Research Site
Amstelveen, , Netherlands
Research Site
Amsterdam, , Netherlands
Research Site
Arnhem, , Netherlands
Research Site
Bennebroek, , Netherlands
Research Site
Boxmeer, , Netherlands
Research Site
Breda, , Netherlands
Research Site
Doetinchem, , Netherlands
Research Site
Echt, , Netherlands
Research Site
Enkhuizen, , Netherlands
Research Site
Enschede, , Netherlands
Research Site
Haarlem, , Netherlands
Research Site
Halsteren, , Netherlands
Research Site
Helmond, , Netherlands
Research Site
Heythuysen, , Netherlands
Research Site
Hoorn, , Netherlands
Research Site
Kerkrade, , Netherlands
Research Site
Kloetinge, , Netherlands
Research Site
Leeuwarden, , Netherlands
Research Site
Maastricht, , Netherlands
Research Site
Nijmegen, , Netherlands
Research Site
Oegstgeest, , Netherlands
Research Site
Raalte, , Netherlands
Research Site
Roermond, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Sluis, , Netherlands
Research Site
Tiel, , Netherlands
Research Site
Tilburg, , Netherlands
Research Site
Utrecht, , Netherlands
Research Site
Veenendaal, , Netherlands
Research Site
Venray, , Netherlands
Research Site
Vlaardingen, , Netherlands
Research Site
Weert, , Netherlands
Research Site
Zaandam, , Netherlands
Research Site
Zoetermeer, , Netherlands
Research Site
Zwolle, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NNL-SER-2008/1
Identifier Type: -
Identifier Source: org_study_id